Ann: Generics Sales Update, page-10

@Rebeki88 - agreed..but the market doesn't seem to have the same point of view.
I guess it's about seeing the figures hit the bottom line.
A few unknown factors are obviously present including how much product was shipped to Mayne Pharma and what percentage of revenue share is involved. For them to have to re-order the 180mg & 250mg much sooner than anticipated, and in quantities/value greater than the initial launch amount is a great sign that things are going well on that end.

Cash in the bank and with another $6.8M to add to it from the remainder of the CMAX sale things are looking very nice here.

They do have to pay Sandoz milestone payments of US$3M (in $1M tranches)
{'There are three milestone payments of US$1.0 million which become payable to Sandoz on achievement of cumulative sales milestones in relation to the ANDA’s purchased in December 2014.'} but that seems to be their only liability which will be easily satisfied.

Add to this their product line to be launched over time and that 22c will be a memory, never mind the current 15c, imo.